A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

A recent abstract published in Nature Communications outlines a new, easy-to-use tool that could help guide early treatment discussions for people with mHSPC. In a nutshell, the innovative system ...

Increasing use of blood tests to detect prostate cancer is leading to overworked doctors. NTNU has now created an AI ...

India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is ...

California-based Artera, a company that develops multimodal AI-based prognostic and predictive cancer tests, has been granted de novo authorization by the FDA for its AI tool for prostate cancer ...

Editor's note: second of two parts; read part one here.. In the first part of our series, we described how PSA is used as a screening tool to help detect prostate cancer in men who don't have symptoms ...

Prostate cancer is one of the most common cancers affecting men around the world. It develops in the prostate, a small gland ...

Financial Distress Screening and Financial Navigation Among Adolescents and Young Adults Within the National Cancer Institute Community Oncology Research Program: Results of the 2022 Landscape Survey ...

Prostate cancer is the most common form of cancer among men in Western countries. The disease is naturally linked to aging. Professor Tone Frost Bathen at NTNU leads a number of research projects on ...

Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology “The breadth and depth of Decipher-focused data ...